2026-01-02 - Analysis Report
Okay, here's a comprehensive report on TG Therapeutics (TGTX), incorporating the data you've provided, structured for clarity and analysis.

**1) Return Comparison with S&P 500 (VOO)**

*   **Company Overview:** TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.

*   **Return Performance:**

    *   TGTX Cumulative Return: 72.74%
    *   VOO Cumulative Return: 105.07%
    *   Divergence: -32.3 (Relative Divergence: 15.5)

*   **Analysis:** TGTX has underperformed the S&P 500 over the period for which the cumulative return is calculated. The divergence of -32.3 means that TGTX has significantly lower cumulative returns compared to VOO. The relative divergence of 15.5 suggests that this underperformance is near the lower end of its historical range, relative to the S&P 500. In other words, the underperformance is not at the absolute worst, but it's still significant.

*   **Alpha, Beta Analysis**

| Year       | CAGR    | MDD    | Alpha   | Beta | Cap(B) |
|------------|---------|--------|---------|------|--------|
| 2016-2018  | -50.0%  | 71.3%  | -79.0%  | 1.8  | 0.7    |
| 2017-2019  | 131.0%  | 83.1%  | 90.0%   | 1.8  | 1.8    |
| 2018-2020  | 352.0%  | 83.1%  | 320.0%  | 1.6  | 8.3    |
| 2019-2021  | 363.0%  | 79.7%  | 287.0%  | 1.6  | 3.0    |
| 2020-2022  | -17.0%  | 94.7%  | -36.0%  | 1.9  | 1.9    |
| 2021-2023  | -65.0%  | 94.7%  | -93.0%  | 2.4  | 2.7    |
| 2022-2024  | 160.0%  | 83.7%  | 130.0%  | 2.3  | 4.8    |
| 2023-2025  | 96.0%   | 83.1%  | 28.0%   | 1.1  | 4.7    |

*   **CAGR:** The Compound Annual Growth Rate shows volatile performance. Periods of very high growth (e.g., 2018-2021) are interspersed with periods of significant decline (e.g., 2016-2018, 2021-2023).
*   **MDD:** The Maximum Drawdown figures are consistently high, indicating substantial risk.
*   **Alpha:** Alpha is generally very high during growth periods and very low during decline periods. This suggests TGTX's performance is significantly impacted by company-specific events or market sentiment toward the company, rather than broad market movements.
*   **Beta:** Beta is consistently above 1, indicating that TGTX is more volatile than the S&P 500.
*   **Cap(B):** The market capitalization fluctuates significantly over the years, reflecting the changing valuation of the company.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** \$29.81
*   **Previous Close:** \$29.75
*   **Change:** + \$0.20 (0.2%)
*   **5-day SMA:** 30.386
*   **20-day SMA:** 30.849
*   **60-day SMA:** 32.3919

*   **Analysis:** The stock price shows a very slight increase in the last trading session. All three moving averages are above the current price, indicating a short-term downward trend. The 5-day SMA is closest to the current price, the 20-day SMA is a bit higher, and the 60-day SMA is the highest, confirming a recent decline.

**3) RSI, PPO, and Market Risk Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 44.78
*   **PPO:** -0.189
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (31 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) Relative Divergence Change:** -0.8 (short-term decline)
*   **Expected Return (%):** 0.0%

*   **Analysis:**
    *   **MRI:** The high MRI score of 0.9 suggests that, according to this indicator, the investment is considered relatively safe, despite the observed volatility.
    *   **RSI:** An RSI of 44.78 is neutral, not indicating overbought or oversold conditions.
    *   **PPO:** The negative PPO (-0.189) indicates that the short-term moving average is below the long-term moving average, further confirming a short-term downward trend.
    *   **Hybrid Signal:** The Hybrid Signal recommends fully investing available cash, suggesting a buying opportunity based on the model's criteria.
    *   **Divergence Change:** The negative change in relative divergence suggests a short-term decline in performance relative to the S&P 500.
    *   **Expected Return:** The 0.0% expected return is concerning, as it indicates no anticipated excess return compared to the S&P 500 over the long term.

**4) Recent News & Significant Events**

*   **Key Headlines & Themes:**

    *   **Wall Street Analysis:** Seeking Alpha article suggests potential discrepancies between Wall Street's view and the company's actual performance.
    *   **Financial Strength:** Yahoo Finance article discusses the company's financials and their potential strength despite recent stock weakness.
    *   **Earnings Caveat:** Investor's Business Daily highlights a negative aspect of recent earnings that caused a stock decline.
    *   **Results Call & Business Update:** TG Therapeutics scheduled a Q3 results call and business update.
    *   **Financial Prospects:** simplywall.st article questions whether the market is undervaluing TG Therapeutics based on its financials.
    *   **Analyst Recommendations:** MarketBeat reports a "Moderate Buy" consensus from brokerages.

*   **Analysis:** The news headlines present a mixed picture. While some articles point to potential undervaluation and strong financials, others highlight concerns about earnings and stock weakness. The overall sentiment seems cautiously optimistic, with analysts generally rating the stock as a moderate buy, but with caveats.

**4-2) Analyst Opinions**

*   **Consensus:** Moderate Buy
*   **Target Price (avg/high/low):** \$44.29 / \$60.00 / \$13.00

*   **Analysis:** The moderate buy consensus suggests that analysts generally see upside potential in the stock. However, the wide range in target prices (from \$13 to \$60) indicates considerable uncertainty and disagreement among analysts regarding the company's future prospects. The absence of recent rating changes makes it difficult to gauge the current analyst sentiment.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-11-05 | 2.69 | 0.16 B$    |
| 2025-08-08 | 0.19 | 0.14 B$    |
| 2025-05-09 | 0.03 | 0.12 B$    |
| 2024-11-07 | 0.03 | 0.08 B$    |
| 2025-11-05 | 0.03 | 0.08 B$    |

*   **Analysis:** The most recent EPS of 2.69 is significantly higher than previous quarters. Revenue has also shown growth over the past few quarters. This suggests a positive trend in the company's financial performance. However, the large jump in EPS in the most recent quarter warrants further investigation to understand the underlying drivers (e.g., one-time gains, cost reductions, etc.).

**6) Financial Information**

*   **Revenue and Profitability**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | \$0.16B  | 82.63%        |
| 2025-06-30 | \$0.14B  | 86.58%        |
| 2025-03-31 | \$0.12B  | 87.14%        |
| 2024-12-31 | \$0.11B  | 85.77%        |
| 2024-09-30 | \$0.08B  | 88.86%        |

*   **Capital and Profitability**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-09-30 | \$0.61B  | 64.37%  |
| 2025-06-30 | \$0.28B  | 10.20%  |
| 2025-03-31 | \$0.24B  | 2.13%   |
| 2024-12-31 | \$0.22B  | 10.49%  |
| 2024-09-30 | \$0.19B  | 2.02%   |

*   **Analysis:**
    *   **Revenue:** Revenue shows consistent growth over the past few quarters.
    *   **Profit Margin:** The profit margins are exceptionally high, which is noteworthy. This could indicate strong pricing power or efficient operations. Further investigation is needed to understand the sustainability of these margins.
    *   **Equity:** Equity has increased significantly, especially in the most recent quarter.
    *   **ROE:** The Return on Equity (ROE) is very high in the most recent quarter, corresponding with the increase in equity and profit. However, ROE was significantly lower in previous quarters. The recent surge in ROE warrants careful consideration to determine if it is sustainable or due to temporary factors.

**7) Comprehensive Analysis (Summary)**

*   **Overall Assessment:** TG Therapeutics presents a mixed investment picture.

*   **Positives:**
    *   Recent positive earnings surprise and revenue growth.
    *   Exceptionally high profit margins.
    *   High MRI score indicating medium investment risk.
    *   Analyst consensus of Moderate Buy.
    *   The hybrid signal gives a buy signal.

*   **Negatives/Risks:**
    *   Underperformance compared to the S&P 500, the stock shows divergence.
    *   Historical volatility (high beta and MDD).
    *   Short-term downward trend in stock price (SMA analysis).
    *   0.0% expected return compared to S&P 500.
    *   Mixed news sentiment with concerns about earnings weakness.
    *   Wide range in analyst target prices indicating uncertainty.
    *   The surge in EPS and ROE in the most recent quarter requires careful examination.
    *   Beta shows it is highly correlated and highly volatile with the market.

*   **Conclusion:** TG Therapeutics appears to be a high-risk, high-reward investment. The recent positive earnings and revenue trends are encouraging, but the stock's historical volatility and underperformance relative to the S&P 500 are significant concerns. Investors should carefully weigh the potential upside against the risks and conduct thorough due diligence before making an investment decision. The recent surge in EPS and ROE requires particularly close scrutiny to ensure it is sustainable.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.